- Home
- TYRA vs NAT Comparison
TYRA vs NAT Comparison
Compare TYRA & NAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- NAT
- Stock Information
- Founded
- TYRA 2018
- NAT 1995
- Country
- TYRA United States
- NAT Bermuda
- Employees
- TYRA N/A
- NAT N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- NAT Marine Transportation
- Sector
- TYRA Health Care
- NAT Consumer Discretionary
- Exchange
- TYRA Nasdaq
- NAT Nasdaq
- Market Cap
- TYRA 571.9M
- NAT 603.5M
- IPO Year
- TYRA 2021
- NAT 1997
- Fundamental
- Price
- TYRA $11.71
- NAT $3.05
- Analyst Decision
- TYRA Strong Buy
- NAT Hold
- Analyst Count
- TYRA 7
- NAT 2
- Target Price
- TYRA $30.43
- NAT $3.50
- AVG Volume (30 Days)
- TYRA 201.1K
- NAT 1.7M
- Earning Date
- TYRA 08-14-2025
- NAT 09-02-2025
- Dividend Yield
- TYRA N/A
- NAT 11.15%
- EPS Growth
- TYRA N/A
- NAT N/A
- EPS
- TYRA N/A
- NAT 0.17
- Revenue
- TYRA N/A
- NAT $327,115,000.00
- Revenue This Year
- TYRA N/A
- NAT N/A
- Revenue Next Year
- TYRA N/A
- NAT $6.07
- P/E Ratio
- TYRA N/A
- NAT $18.05
- Revenue Growth
- TYRA N/A
- NAT N/A
- 52 Week Low
- TYRA $6.42
- NAT $2.13
- 52 Week High
- TYRA $29.60
- NAT $3.83
- Technical
- Relative Strength Index (RSI)
- TYRA 61.31
- NAT 65.71
- Support Level
- TYRA $9.96
- NAT $2.82
- Resistance Level
- TYRA $11.48
- NAT $2.90
- Average True Range (ATR)
- TYRA 0.73
- NAT 0.08
- MACD
- TYRA 0.06
- NAT 0.02
- Stochastic Oscillator
- TYRA 75.43
- NAT 93.10
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.